Descripción de la empresa
Generation Bio Co. operates within the healthcare sector, specifically focusing on the biotechnology industry, where it discovers, develops, and commercializes redosable therapeutics designed to reprogram T cells in vivo. This operational model aims to reduce or eliminate the production and persistence of autoreactive T cells, utilizing cell-targeted lipid nanoparticles to selectively deliver small molecules. The company maintains a market capitalization of $35.98M and generates annual revenue of $15.27M, supported by a workforce of 115 employees. These financial figures indicate that Generation Bio Co. functions as a mid-sized entity within the biotechnology landscape, possessing a valuation that reflects early-stage growth characteristics typical of firms prioritizing research and development over immediate profitability.
Salud financiera
The company reported a revenue of $15.27M for the trailing twelve months, yet it posted a net income of $-62,627,000 and an EBITDA of $-76,380,000. The substantial gap between the $15.27M revenue and the negative net income reveals a cost structure where operating expenses significantly exceed gross revenue, resulting in a loss on every dollar of sales. Free cash flow stands at $-40,196,752, indicating that the company is currently consuming cash reserves to fund its operations and development pipeline rather than generating surplus liquidity. Margins across the board are negative, with a gross margin of -212.2%, an operating margin of -2020.0%, and a profit margin of 0.0%, which collectively highlight the high burn rate inherent in developing cell-targeted lipid nanoparticle technologies before reaching commercial scale. On the balance sheet, the company holds $89.62M in cash against $26.10M in debt, resulting in a debt-to-equity ratio of 51.61. Despite the negative earnings, the cash position is more than three times the debt load, suggesting a conservative liquidity stance relative to obligations, although the high leverage ratio reflects the equity base's dilution or negative book value. The current ratio is 4.44, indicating strong short-term liquidity where current assets are more than four times current liabilities, providing ample buffer for meeting immediate financial commitments. Return on Equity is -80.8% and Return on Assets is -27.4%, metrics that reveal management is currently destroying shareholder value and utilizing assets inefficiently in terms of profit generation.
Evaluación de valoración
Valuation metrics present a complex picture, with a P/E Ratio (TTM) listed as N/A due to negative earnings and a forward P/E of -3.99, implying that the market expects earnings to improve or that the current price does not reflect a standard earnings multiple. The price-to-book ratio is 0.71, suggesting the stock trades at a discount to its book value, which often occurs when investors price in significant risks regarding future profitability and the inability to generate returns above the cost of equity. Alternative valuation measures include a price-to-sales ratio of 2.36 and an EV/EBITDA of 0.36, which indicate that the market values the company based on its sales and enterprise value relative to its negative earnings power. The 52-week high is $7.60 and the 52-week low is $3.00, providing a trading range within which the stock has fluctuated over the past year. The beta value of 2.01 indicates that the stock's price volatility is roughly twice that of the broader market, meaning it experiences amplified swings during periods of market uncertainty.
Growth & Income
Revenue growth (YoY) stands at -78.9%, while earnings growth (YoY) is N/A due to the lack of positive earnings data to calculate a year-over-year increase. The contraction in revenue suggests a challenging period for commercialization or sales, and since earnings are negative, the relationship between revenue decline and earnings performance cannot be interpreted as a divergence in profitability trends. As a non-dividend payer, Generation Bio Co. does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company reinvests all available cash flow, if any, back into its R&D and operational infrastructure. The overall growth and income profile is characterized by significant revenue contraction and a complete absence of distributable earnings or dividends, reflecting the typical trajectory of a biotechnology firm still navigating the path toward product approval and commercial viability.